Skip to content

Add-on benefit of cerebrolysin to acute stroke patients given recombinant tissue plasminogen activator

Multi-center trial on the efficacy of cerebrolysin in acute ischemic stroke after intravenous thrombolysis

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN61644835
Enrollment
60
Registered
2025-07-03
Start date
2024-05-24
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke after intravenous thrombolysis Circulatory System

Interventions

Patients will be randomized using the research randomizer to either the treatment group or the control group. The research randomizer (randomizer.org) is a free online software used to generate random

Sponsors

Baguio General Hospital and Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. >18 years old 2. Having an acute ischemic stroke within 4.5 hours post-ictus, moderate to severe stroke with NIHSS 10-25 on admission 3. Meets criteria for intravenous thrombolysis

Exclusion criteria

Exclusion criteria: 1. Hemorrhagic strokes on baseline CT scan 2. History of hepatic failure 3. History of chronic kidney disease (creatinine clearance <30) 4. Stroke mimickers

Design outcomes

Primary

MeasureTime frame
Degree of independence or disability measured using the Modified Rankin Scale (MRS) at discharge and 3 months

Secondary

MeasureTime frame
1. Symptomatic ICH assessed using CT scan at baseline (admission), 24 hours and 5 days 2. Degree of cognitive dysfunction measured using the Montreal Cognitive Assessment (MoCA) test at 3 months 3. Degree of stroke severity measured using the National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) at baseline (admission), 24 hours, discharge and 3 months

Countries

Philippines

Contacts

Public ContactPeter Allan Quitasol
peterallanquitasol@gmail.com+63 (0)917 585 5131

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026